Intravesical Oxybutynin for Neurogenic Bladder in Children
- *Corresponding Author:
- Motoaki Saito, MD
Division of Molecular Pharmacology
Tottori University School of Medicine
86 Nishimachi, Yonago 683-8503, Japan
E-mail: [email protected]
Received Date: June 19, 2012; Accepted Date: September 24, 2012; Published Date: September 26, 2012
Citation: Inoue S, Saito M, Honda M, Dimitriadis F, Takenaka A (2012) Intravesical Oxybutynin for Neurogenic Bladder in Children. Pediat Therapeut 2:138. doi: 10.4172/2161-0665.1000138
Copyright: © 2012 Inoue S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Neuropathic bladder dysfunction caused by spinal cord disease may lead to irreversible renal damage and urinary incontinence. The majority of affected children can be successfully managed with standard medical treatment such as oral anti-cholinergic medication (typically oxybutynin or tolterodine) with or without Clean Intermittent Catheterization (CIC). The efficacy of this treatment, however, may be hampered as some of these patients experience severe Adverse Events (AEs) or insufficient suppression of detrusor over activity following oral anti-muscarinic pharmacotherapy. Intravesical oxybutynin chloride is an effective therapy for neurogenic bladder dysfunction; this review considers the indications, administration, safety, and efficacy of intravesical oxybutynin chloride instillation. In addition, some cases of children treated with intravesical oxybutynin chloride solution supplemented with hydroxypropylcellulose (modified intravesical oxybutynin) are described.